The 6% naturally derived extract is set to be encapsulated for use in patients suffering from treatment-resistant depression under Australia's Authorised Prescriber Scheme, where no serious adverse ...
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian ...
Psilocybin has appeared in a number of biotech pipelines as the sector investigates whether psychedelics could improve treatment for certain mental health conditions. Relmada Therapeutics’ attempts to ...
The approval to initiate this Phase 2 clinical trial represents a pivotal moment in the clinical development of Optimi's GMP natural psilocybin extract capsules. Building on its established status as ...
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health Canada, ...
The Company's natural psilocybin extract powers a culturally transformative study to address methamphetamine addiction through indigenous frameworks. The study is the first of its kind, combining ...
VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results